CD19 and lymphoma: PEGylated liposomes conjugated to the internalizing receptor CD19, which is overexpressed in various B-lymphoid cancers, showed improved efficacy in a human CD19+ B-lymphoma mouse model compared to non-antibody conjugated liposomes [189,190].